USS Investment Management Ltd Raises Stock Holdings in Edwards Lifesciences Corporation $EW

USS Investment Management Ltd boosted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 8.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 126,927 shares of the medical research company’s stock after buying an additional 9,504 shares during the quarter. USS Investment Management Ltd’s holdings in Edwards Lifesciences were worth $10,165,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in EW. IFM Investors Pty Ltd increased its position in shares of Edwards Lifesciences by 3.1% in the first quarter. IFM Investors Pty Ltd now owns 133,340 shares of the medical research company’s stock valued at $10,678,000 after acquiring an additional 3,954 shares during the period. iA Global Asset Management Inc. purchased a new stake in shares of Edwards Lifesciences during the first quarter worth about $574,000. Premier Path Wealth Partners LLC grew its stake in shares of Edwards Lifesciences by 4.4% in the first quarter. Premier Path Wealth Partners LLC now owns 3,880 shares of the medical research company’s stock worth $311,000 after purchasing an additional 162 shares during the last quarter. Caliber Wealth Management LLC KS grew its stake in shares of Edwards Lifesciences by 10.0% in the first quarter. Caliber Wealth Management LLC KS now owns 23,836 shares of the medical research company’s stock worth $1,909,000 after purchasing an additional 2,162 shares during the last quarter. Finally, Asset Planning Inc increased its holdings in Edwards Lifesciences by 1.1% during the 1st quarter. Asset Planning Inc now owns 26,213 shares of the medical research company’s stock valued at $2,099,000 after purchasing an additional 286 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. BTIG Research increased their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Evercore reaffirmed an “outperform” rating and issued a $93.00 target price on shares of Edwards Lifesciences in a research report on Friday, April 24th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a research note on Wednesday, April 1st. Finally, Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.39.

Edwards Lifesciences Price Performance

Shares of EW opened at $91.95 on Thursday. The stock has a market cap of $52.95 billion, a PE ratio of 48.91, a price-to-earnings-growth ratio of 2.27 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $92.88. The firm’s 50-day simple moving average is $85.06 and its two-hundred day simple moving average is $83.41.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s revenue was up 16.7% on a year-over-year basis. During the same period last year, the business earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 58,977 shares of company stock valued at $4,921,803. 0.31% of the stock is owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.